| 周子力,蒲光林,丛 林,李宜为,胡 文.五酯丸联合阿德福韦酯对慢性乙型肝炎患者肝功能及血清细胞因子IL-17、IL-22的影响[J].,2021,(4):706-709 |
| 五酯丸联合阿德福韦酯对慢性乙型肝炎患者肝功能及血清细胞因子IL-17、IL-22的影响 |
| Effects of Wuzhi Pill Combined with Adefovir Dipivoxil on Liver Function and Serum Cytokines IL-17 and IL-22 in Patients with Chronic Hepatitis B |
| 投稿时间：2020-04-28 修订日期：2020-05-23 |
| DOI：10.13241/j.cnki.pmb.2021.04.022 |
| 中文关键词: 五酯丸 阿德福韦酯 慢性乙型肝炎 肝功能 白介素-17 白介素-22 |
| 英文关键词: Wuzhi pill Adefovir dipivoxil Chronic hepatitis B Liver function Interleukin -17 Interleukin -22 |
| 基金项目:四川省科技厅计划项目（2016JY0657） |
|
| 摘要点击次数: 680 |
| 全文下载次数: 412 |
| 中文摘要: |
| 摘要 目的：探讨五酯丸联合阿德福韦酯对慢性乙型肝炎（CHB）患者肝功能及血清细胞因子白介素-17（IL-17）、白介素-22（IL-22）的影响。方法：选取2016年3月~2018年3月期间我院收治的CHB患者118例，根据随机数字表法分为对照组（n=59）和研究组（n=59），对照组患者给予阿德福韦酯治疗，研究组在对照组的基础上联合五酯丸治疗，比较两组患者疗效、肝功能指标[门冬氨酸氨基转氨酶（AST）、丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）]、血清细胞因子IL-17、IL-22、乙肝病毒基因（HBV-DNA）以及乙型肝炎病毒e抗原（HBeAg）阴转情况，记录两组治疗期间不良反应情况。结果：研究组治疗6个月后的临床总有效率为93.22%（55/59），高于对照组患者的79.66%（47/59）（P<0.05）。两组治疗6个月后ALT、AST、TBIL均下降，且研究组低于对照组（P<0.05）。两组治疗6个月后IL-17、IL-22均下降，且研究组低于对照组（P<0.05）。两组患者HBV-DNA、HbeAg阴转率比较均无统计学差异（P>0.05）。两组不良反应发生率对比未见统计学差异（P>0.05）。结论：五酯丸联合阿德福韦酯治疗CHB患者，虽不会增加抗病毒应答，但可改善机体肝功能，降低血清细胞因子IL-17、IL-22水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Wuzhi pill combined with adefovir dipivoxil on liver function and serum cytokines Interleukin-17 (IL-17), Interleukin-22 (IL-22) in patients with chronic hepatitis B (CHB). Methods: 118 CHB patients wwho were admitted to our hospital from March 2016 to March 2018 were selected, they were divided into control group (n = 59) and study group (n= 59) according to the method of random number table. Patients in the control group were treated with adefovir dipivoxil, and the study group was treated with Wuzhi Pill on the basis of the control group. The curative effect and Liver function index [aspartate aminotransferase (AST), alanine aminotransferase (ALT), Total bilirubin (TBIL)], serum cytokines IL-17, IL-22, the negative situation of serum cytokine hepatitis B virus gene (HBV-DNA) and hepatitis Be antigen (HBeAg), the adverse reactions were recorded during the treatment. Results: The total clinical effective rate of the study group was 93.22% (55/59), which was higher than 79.66% (47/59) of the control group (P<0.05). Alt, AST and TBIL decreased in the two groups after 6 months of treatment, and the level in the study group was lower than that in the control group (P<0.05). IL-17 and IL-22 decreased in the two groups after 6 months of treatment, and the level in the study group was lower than that in the control group (P<0.05). There was no significant difference in HBV-DNA and HBeAg negative conversion rate between the two groups (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Wuzhi pill combined with adefovir dipivoxil can not increase the antiviral response, but can improve the liver function and reduce the level of serum cytokines serum cytokines IL-17 and IL-22. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
